



Celltex has worked with thousands of individuals.

While results vary, high-dose Mesenchymal Stem Cell (MSC) therapy has the potential to produce truly life-changing results.

Our clients have seen the most significant results with conditions like:

- Osteoarthritis
- Inflammatory arthritis
- Multiple sclerosis
- Parkinson's disease

SUPPORTING INFORMATION

The provided data stems from studies conducted by the Celltex Research & Development Team:

Safety Registry Study Series using Autologous Adipose-Derived Mesenchymal Stem Cells: Osteoarthritis of the Knee – Retrospective Patient-Reported Outcomes.

Safety Registry Study Series using Autologous Adipose-Derived Mesenchymal Stem Cells: Osteoarthritis of the Shoulder – Prospective and Retrospective Patient-Reported Outcomes, 2020.

Patient Reported Outcomes: Prospective/Retrospective Surveys of Patients with Inflammatory Arthritis treated with Autologous Mesenchymal Stem Cells, 2021 Update.

Patient Reported Outcomes: Retrospective Surveys of Multiple Sclerosis Patients Receiving Autologous Mesenchymal Stem Cell Therapy, 2016.

Safety Registry Study Series using Autologous Adipose-Derived Mesenchymal Stem Cells. Parkinson's Disease – Prospective/Retrospective Patient-Reported Outcomes, 2021.

DISCLAIMER: The Celltex Client Reported Outcomes are being shared with you at your request. It reflects actual outcomes from individuals who received therapy using Celltex-produced mesenchymal stem cells. The study shows positive results for these individuals. It is important to note that the study is not scientific. No representation is being made that you or any other individual would get similar positive results. You should consult with your physician on what is best for you. Please call us if you wish to find out more about Celltex and the positive results individuals are having as reflected in this study.

CLIENT REPORTED OUTCOMES

OSTEOARTHRITIS (OA)

The data provided is based on reports from Celltex clients regarding the results of their therapy relating to either osteoarthritis of the knee or shoulder.

Clients that did not respond to data collection were not included in results.

OA-Knee (OA-K) Symptom Improvement

81% of clients with OA-K

reported that one or more symptom improved.

86% of OA-K symptoms

improved on average for the **81%** reporting improvement.

86% of clients with OA-K

said they would recommend MSC therapy to others with OA-K.

OA-Shoulder (OA-S) Symptom Improvement

83% of clients with OA-S

reported that one or more symptom improved.

90% of OA-S symptoms

improved on average for the **83%** reporting improvement.

95% of clients with OA-S

said they would recommend MSC therapy to others with OA-S.


In addition to improvements reported by clients, **physicians saw range of motion in the shoulders of OA-S clients increase by an average of ten points.**



OSTEOARTHRITIS, KNEE (OA-K)

A Closer Look at the Symptoms


The chart below represents the percentage of respondents that reported seeing improvement for their indicated symptom. Not every individual had every symptom.



OSTEOARTHRITIS, SHOULDER (OA-S)

A Closer Look at the Symptoms

The chart below represents the percentage of respondents that reported seeing improvement for their indicated symptom. Not every individual had every symptom.



CLIENT REPORTED OUTCOMES

INFLAMMATORY ARTHRITIS (IA)

The data provided is based on reports from clients regarding the results of their therapy relating to inflammatory types of arthritis, such as psoriatic, rheumatoid, or juvenile idiopathic arthritis.

Clients that did not respond to data collection were not included in results.

IA Symptom Improvement

Results were determined by the number of symptoms each client saw improvements in, as well as the level at which these symptoms improved.

100% of IA clients

reported improvements in one or more symptoms.

88% of IA symptoms

showed some level of improvement on average.

90% of clients with IA

said they would recommend MSC therapy to others with IA.

Physician-Validated Improvement for IA


In addition to improvements reported by clients, **71% of clients with IA showed physician-validated improvement through the standardized ACR20 evaluation.**



INFLAMMATORY ARTHRITIS (IA)

A Closer Look at the Symptoms

The chart below represents the percentage of respondents that reported seeing improvement for their indicated symptom. Not every individual had every symptom.



PROMISING POTENTIAL

There's no such thing as guaranteed results.


While there are no guaranteed results for any therapy or drug, it's clear that high-dose MSC therapy has **the potential to yield significant results without the costly side effects** of most disease modifying interventions and prescriptions.

UNIQUE APPROACH

Celltex does what other labs can't.

Our proprietary technology produces a pure, potent bank of MSCs in never before seen quantities.

Thanks to their superior quality and quantity, Celltex-produced MSCs have the potential to succeed where same day stem cell therapies have failed before.



THINGS TO KNOW

- **Studies show that MSC therapy is safe.**

Celltex-produced MSCs have been [used in over 10,000 therapies](#) with no severe adverse events.

- **You can start MSC banking at any age.**

While it's true that younger MSCs are more effective – [Celltex's cultivation process allows individuals of all ages](#) to obtain high doses of their own stem cells.

- **Celltex MSCs come from your own body.**

Your Celltex Stem Cell Bank contains MSCs [extracted from your own body during a simple, 30-minute outpatient procedure.](#)

- **Our lab is FDA-Registered.**

Celltex's laboratory meets or exceeds all current Good Manufacturing Practices (cGMP) regulations, and [all Celltex operations are compliant with FDA guidelines and procedures.](#)

THERAPY PROCESS

- Administration routes vary by client need.

Intravenous (IV) administration is the most common method of MSC therapy. Other common administration routes include: Intranasal (IN), Intraarticular (IA), Intradiscal (IDISC), and Intrathecal (IT).

- Therapy appointments are usually 1-3 hours long.

Therapy appointments vary based on dosage and condition but generally take 1-3 hours. Clients are usually able to immediately resume normal activities after therapy.

- Celltex does not administer the therapy.

Once your Celltex Stem Cell Bank is established, we will work with you and a licensed physician to coordinate your therapy.

- The cost of therapy may vary.

The cost of therapy varies according to individual needs, conditions, and physician recommendations. Contact your Client Service Coordinator for information on pricing.

THE ROAD FORWARD



Your results could help advance the future of regenerative medicine.

Scientists are only beginning to grasp the full potential of MSC therapy, but by banking with Celltex **you're helping build a brighter future for regenerative medicine.**



CELLTEX[®]

Ask your Client Service Coordinator how you can continue the banking process today.